In vitroactivities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens
Authors:
- 20 May 2009
- journal article
- research article
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 123 (9) , 978-981
Abstract
Objective: To determine the causative pathogens of otomycosis, and to evaluate thein vitroactivity of antifungal agents against these pathogens.Materials and methods: A total of 96 fungal isolate were taken from 92 patients suspected of otomycosis. Thein vitroactivity of fluconazole, itraconazole and voriconazole against otomycotic pathogens was tested using the E-test method.Results: The most common pathogen wasAspergillus fumigatus(40.6 per cent), followed byA niger(35.4 per cent),A flavus(12.5 per cent) andCandida albicans(11.5 per cent). AllAspergillusspecies were found to be resistant to fluconazole (minimum inhibitory concentration ≥256 µg/ml). The mean minimum inhibitory concentrations of voriconazole forA fumigatus,A niger,A flavusandC albicanswere significantly lower than those of itraconazole for the same pathogens.Conclusion: This study found that the most common otomycotic fungal pathogen wasA fumigatus, and that voriconazole had more potentin vitroactivity than itraconazole against allAspergillusspecies as well as againstC albicans.Keywords
This publication has 19 references indexed in Scilit:
- Otogenic skull base osteomyelitis caused by invasive fungal infectionEuropean Archives of Oto-Rhino-Laryngology, 2006
- In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans , and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution MethodsJournal of Clinical Microbiology, 2005
- In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest®: results of a French multicentre studyInternational Journal of Antimicrobial Agents, 2005
- Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001Journal of Clinical Microbiology, 2003
- In Vitro Susceptibility Testing of Aspergillus spp.: Comparison of Etest and Reference Microdilution Methods for Determining Voriconazole and Itraconazole MICsJournal of Clinical Microbiology, 2003
- Otomycosis in Turkey: predisposing factors, aetiology and therapyThe Journal of Laryngology & Otology, 2003
- Nationwide Survey of In Vitro Activities of Itraconazole and Voriconazole against Clinical Aspergillus fumigatus Isolates Cultured between 1945 and 1998Journal of Clinical Microbiology, 2002
- E-Test Method for Testing Susceptibilities of Aspergillus spp. to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution MethodJournal of Clinical Microbiology, 2002
- In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazoleJournal of Antimicrobial Chemotherapy, 1999
- Invasive External Otitis Caused by AspergillusClinical Infectious Diseases, 1990